Advancing gene therapy development with a multi-serotype AAV affinity resin

Tuesday 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET

Sponsor

Advancing gene therapy development with a multi-serotype AAV affinity resin

Adeno-associated virus (AAV) has emerged as a leading vector for gene delivery for treating various diseases due to its safety profile and efficient transduction of various target tissues. Yet, advances in purification tools and techniques are needed to dependably develop and manufacture high quality AAV. A platform purification process for various AAV serotypes is a crucial step supporting the continued emergence of the commercial gene therapy sector.

In this webinar, leading CDMO ABL and Thermo Fisher will share data on implementation of the POROS™ CaptureSelect™ AAVX affinity resin into such an AAV purification platform, including its performance in purifying several serotypes.

Attendees will learn about:

Considerations for a platform affinity chromatography step helps to achieve high purity, high yield, and high recovery in AAV production for a variety of serotypes.
How utilization of the POROS™ CaptureSelect™ AAVX resin can result in significant improvement to the downstream process of AAV
Advancements in AAV vector purification and insights on future developments in the downstream process of this gene therapy vector.

Nicolas Laroudie

Senior Field Application Specialist at Thermo Fisher Scientific

Biochemist by education, Nicolas Laroudie worked at Généthon, France between 2001 and 2011 as Head of Downstream Development. He led a team developing and scaling-up purification processes for AAV, retroviral and lentiviral vectors used for gene therapy treatments. He then joined Merck Millipore as a BioManufacturing Engineer and supported European customers for all DSP technologies with a strong focus on chromatography. In particular, he took an active role in the establishment of a fully continuous, large-scale disposable DSP process for the purification of a monoclonal antibody, within the framework of a large multi-company European consortium. Next he joined Thermo Fisher Scientific in 2019 as Field Application Specialist for purification, supporting the technical implementation of POROS and CaptureSelect chromatography products in south-western Europe.

Quentin Bazot

Group Leader, Process Development at ABL Europe

Quentin Bazot is a molecular virologist. He received his PhD from the Ecole Normale Supérieure (ENS) de Lyon in 2012. After a postdoctoral training at the Imperial College London, he joined the CGT Catapult where he led viral vector process and manufacturing development activities. In 2020 Quentin joined ABL where he is currently leading AAV process development and innovation programs working towards the optimization of AAV production and purification.